View Post

Study of tagraxofusp reports 90% response rate for deadly blood cancer with no prior available therapies

In Clinical Trials by Barbara Jacoby

Source: University of Texas M. D. Anderson Cancer Center From: eurekalert.org An open-label, multi-cohort Phase II trial, led by investigators at The University of Texas MD Anderson Cancer Center, reports that treatment with the drug tagraxofusp resulted in high response rates in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare but highly aggressive – and often fatal bone …

View Post

AACR 2019: Maintenance Rucaparib Treatment in BRCA- or PALB2-Mutated Pancreatic Cancer

In Clinical Trials by Barbara Jacoby

By: The ASCO Post From: ascopost.com Maintenance treatment with the PARP inhibitor rucaparib was well tolerated and showed activity among patients with advanced BRCA– or PALB2-mutated pancreatic cancer sensitive to platinum-based chemotherapy, according to results from an interim analysis of an ongoing phase II clinical trial presented by Reiss Binder et al at the American Association for Cancer Research (AACR) Annual Meeting …

View Post

Radiation after surgery triples survival for a type of pediatric brain tumor

In Clinical Trials by Barbara Jacoby

By: St. Jude Children’s Research Hospital From: medicalxpress.com Radiation immediately following surgery in children with ependymoma, the third most common pediatric brain tumor, can nearly triple survival. The results are part of a Children’s Oncology Group (COG) clinical trial led by Thomas E. Merchant, D.O., Ph.D., of St. Jude Children’s Research Hospital. The findings appear as an advance online publication …

View Post

Brand new type of cancer drug has potential to fill unmet needs in oncology market

In Clinical Trials by Barbara Jacoby

By: Philippa Salter Source: Global Data “Although cancer treatment has significantly advanced over the past few decades, there are still many ‘difficult-to-treat’ cancers, particularly when they reach more advanced stages. However, this trial showed that tisotumab vedotin caused a response in a significant minority of patients with advanced stage cancer who had already failed to respond to at least 3 …

View Post

High-dose radiation therapy improves long-term survival in patients with stage-IV cancers, trial finds

In Clinical Trials by Barbara Jacoby

Source: American Society for Radiation Oncology From: sciencedaily.com The first report from a phase II, multi-center clinical trial indicates that a newer, more aggressive form of radiation therapy — stereotactic radiation — can extend long-term survival for some patients with stage-IV cancers while maintaining their quality of life. The study is published in the January issue of International Journal of …

View Post

Clinical Trial Saves Life of Stage 4 Kidney Cancer Patient

In Clinical Trials by Barbara Jacoby

By: Bianca Castro From: nbcdfw.com When a well-known journalist in Dallas learned he had stage 4 kidney cancer, he was told he had three, possibly four, years to live. One year, later, the tumor threatening his life is gone and it’s thanks to a clinical trial at UT Southwestern. Robert Wilonsky will tell you there’s nothing special about him. He’ll …

View Post

Mayo researchers ID potential new treatment for one type of triple-negative breast cancer

In Clinical Trials by Barbara Jacoby

Source: Mayo Clinic From: eurekalert.org Mayo Clinic researchers have identified the drug estradiol as a potential new treatment for a subset of women with triple-negative breast cancer. Their findings are published in the Proceedings of the National Academy of Sciences of the United States of America. “Triple-negative breast cancer is a form of breast cancer that lacks expression of estrogen …

View Post

Puma Biotechnology Announces Top Line Results of the Phase III NALA Trial of Neratinib in Patients with HER2-Positive Metastatic Breast Cancer

In Clinical Trials by Barbara Jacoby

SOURCE: Puma Biotechnology, Inc. From: apnews.com Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced top line results from the Phase III NALA trial of the Company’s lead drug candidate PB272 (neratinib) in patients with HER2-positive metastatic breast cancer who have failed two or more prior lines of HER2-directed treatments (third-line disease) in the setting of metastatic disease. The Phase …

View Post

Puma Biotechnology Presents Results of Patient Reported Outcomes in Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer

In Clinical Trials by Barbara Jacoby

From: businesswire.com Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, is presenting updated results from a Phase II clinical trial of Puma’s drug neratinib at the 2018 San Antonio Breast Cancer Symposium (SABCS) that is currently taking place in San Antonio, Texas. The presentation entitled, “The impact of neratinib with or without anti-diarrheal prophylaxis on health-related quality of life in …

View Post

ONC201 Trial Begins for Endometrial and Breast Cancer

In In The News by Barbara Jacoby

Oncoceutics, Inc. announced today that the first patient has been treated in a clinical trial of ONC201 for patients with certain types of advanced endometrial and breast cancer. The Phase II trial is led by Alexandra Zimmer, MD, Assistant Research Physician at the Women’s Malignancies Branch at the National Cancer Institute (NCI) Center for Cancer Research, part of the National …